Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18-30 years) with hemophilia-Reference-Cited by-同舟云学术

Treatment outcomes, quality of life, and impact of hemophilia on young adults (aged 18-30 years) with hemophilia

Published:2015-11-30 Issue: Volume:90 Page:S3-S10
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Witkop Michelle¹,Guelcher Christine²,Forsyth Angela³,Hawk Sarah⁴,Curtis Randall⁵,Kelley Laureen⁶,Frick Neil⁷,Rice Michelle⁷,Rosu Gabriela⁸,Cooper David L.⁹

Affiliation:

1. Munson Medical Center; Traverse City Michigan

2. Children's National Medical Center; Washington DC

3. BioRx; Mason Ohio

4. Oklahoma Center for Bleeding Disorders; Oklahoma City Oklahoma

5. Factor VIII Computing; Berkeley California

6. LA Kelley Communications, Inc; Georgetown Massachusetts

7. National Hemophilia Foundation; New York New York

8. Novo Nordisk Healthcare AG; Zurich Switzerland

9. Clinical, Medical, and Regulatory Affairs, Novo Nordisk Inc; Plainsboro New Jersey

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24220/fullpdf

Reference13 articles.

1. Psychosocial aspects of haemophilia: A systematic review of methodologies and findings;Cassis;Haemophilia,2012

2. A pilot study on the effects of the transition of paediatric to adult health care in patients with haemophilia and in their parents: Patient and parent worries, parental illness-related distress and health-related Quality of Life;Geerts;Haemophilia,2008

3. Parents of children with haemophilia-A transforming experience;Beeton;Haemophilia,2007

4. 2010

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A;Journal of Thrombosis and Haemostasis;2024-07

2. In the pursuit of a healthier diet among young Chinese adults: identifying important food quality attributes and factors that influence food choices;International Journal of Food Science & Technology;2024-04-11

3. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy;Haemophilia;2024-03-10

4. Long‐term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post‐treatment;Haemophilia;2024-02-05

5. Epidemiology, patient journey and unmet needs related to hemophilia in Brazil: a scoping review with evidence map;Hematology, Transfusion and Cell Therapy;2024-02